Cited by 678

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

Thierry, Alain R, Mouliere, Florent, El Messaoudi, Safia, Mollevi, Caroline, Lopez-Crapez, Evelyne, Rolet, Fanny, Gillet, Brigitte, Gongora, Celine, Dechelotte, Pierre, Robert, Bruno, Del Rio, Maguy, Lamy, Pierre-Jean, Bibeau, Frederic, Nouaille, Michelle, Loriot, Virginie, Jarrousse, Anne-Sophie, Molina, Franck, Mathonnet, Muriel, Pezet, Denis, Ychou, Marc·2014·Nature Medicine

DOI 10.1038/nm.3511

Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nm.3511

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Self-citation
Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673
Self-citation
High Fragmentation Characterizes Tumour-Derived Circulating DNA
Mouliere, F., Robert, B., Arnau Peyrotte, E., Del Rio, M., Ychou, M., Molina, F., Gongora, C., & Thierry, A. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023418 · Cited by 567
Self-citation
REporting recommendations for tumor MARKer prognostic studies (REMARK)
for the Statistics Subcommittee of the NCI—EORTC Working Group on Cancer Diagnostics (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0252 · Cited by 561
Circulating cell free DNA: Preanalytical considerations
El Messaoudi, S., Rolet, F., Mouliere, F., & Thierry, A. R. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.05.022 · Cited by 560
Self-citation
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Self-citation
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
Leary, R. J., Kinde, I., Diehl, F., Schmidt, K., Clouser, C., Duncan, C., Antipova, A., Lee, C., McKernan, K., De La Vega, F. M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000702 · Cited by 517
Isolation and characterization of DNA from the plasma of cancer patients
Stroun, M., Anker, P., Lyautey, J., Lederrey, C., & Maurice, P. A. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90266-5 · Cited by 373
Colorectal cancer molecular biology moves into clinical practice
Pritchard, C. C., & Grady, W. M. (2011) · Gut · doi:10.1136/gut.2009.206250 · Cited by 344
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts
Thierry, A. R., Mouliere, F., Gongora, C., Ollier, J., Robert, B., Ychou, M., Del Rio, M., & Molina, F. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq421 · Cited by 299
Self-citation
Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis
Lecomte, T., Berger, A., Zinzindohoué, F., Micard, S., Landi, B., Blons, H., Beaune, P., Cugnenc, P., & Laurent‐Puig, P. (2002) · International Journal of Cancer · doi:10.1002/ijc.10526 · Cited by 292
KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Quantitative Cell-Free DNA, KRAS , and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
Spindler, K.-L. G., Pallisgaard, N., Vogelius, I., & Jakobsen, A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0564 · Cited by 251
Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients
Diehl, F., Schmidt, K., Durkee, K. H., Moore, K. J., Goodman, S. N., Shuber, A. P., Kinzler, K. W., & Vogelstein, B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.039 · Cited by 228
Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
Soh, J., Okumura, N., Lockwood, W. W., Yamamoto, H., Shigematsu, H., Zhang, W., Chari, R., Shames, D. S., Tang, X., MacAulay, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007464 · Cited by 228
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
Board, R. E., Wardley, A. M., Dixon, J. M., Armstrong, A. C., Howell, S., Renshaw, L., Donald, E., Greystoke, A., Ranson, M., Hughes, A., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0747-9 · Cited by 201
The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients
West, N. P., Dattani, M., McShane, P., Hutchins, G., Grabsch, J., Mueller, W., Treanor, D., Quirke, P., & Grabsch, H. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605674 · Cited by 191
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Kim, M. J., Lee, H. S., Kim, J. H., Kim, Y. J., Kwon, J. H., Lee, J., Bang, S., Park, K. U., Kim, D., Kang, S., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-347 · Cited by 145
Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
Mead, R. J., Duku, M., Bhandari, P., & Cree, I. A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.230 · Cited by 122
The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients
Mouliere, F. C., & Thierry, A. R. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.688023 · Cited by 110
Self-citation
A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up
Ryan, B. M., Lefort, F., McManus, R., Daly, J., Keeling, P. W. N., Weir, D. G., & Kelleher, D. (2002) · Gut · doi:10.1136/gut.52.1.101 · Cited by 109
Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
Yen, L.-C., Yeh, Y., Chen, C., Wang, H., Tsai, H., Lu, C.-Y., Chang, Y., Chu, K., Lin, S., & Wang, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3179 · Cited by 102
KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics
Weichert, W., Schewe, C., Lehmann, A., Sers, C., Denkert, C., Budczies, J., Stenzinger, A., Joos, H., Landt, O., Heiser, V., et al. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090079 · Cited by 97
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
de Castro, D. G., Angulo, B., Gomez, B., Mair, D., Martinez, R., Suárez‐Gauthier, A., Shieh, F., Velez, M., Brophy, V. H., Lawrence, H. J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.259 · Cited by 81
KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues
Solassol, J., Ramos, J., Lopez‐Crapez, E., Saifi, M., Mangé, A., Vianès, E., Lamy, P., Costes, V., & Maudelondé, T. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12053191 · Cited by 59
Self-citation
The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: A comparison between direct sequencing and real-time PCR
Kobunai, T., Watanabe, T., Yamamoto, Y., & Eshima, K. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.167 · Cited by 53
Prognostic Value of Circulating Mutant DNA in Unresectable Metastatic Colorectal Cancer
Lefébure, B., Charbonnier, F., Fiore, F. D., Tuech, J., Pessot, F. L., Michot, F., Michel, P., & Frébourg, T. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181c35c87 · Cited by 53
Circulating tumour markers can define patients with normal colons, benign polyps and cancers
Mead, R. J., Bhandari, P., Duku, M., & Cree, I. A. (2011) · Gut · doi:10.1136/gut.2011.239301.4 · Cited by 49
KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
Bando, H., Yoshino, T., Tsuchihara, K., Ogasawara, N., Fuse, N., Kojima, T., Tahara, M., Kojima, M., Kaneko, K., Doi, T., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.247 · Cited by 46
Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy
Oltedal, S., Aasprong, O. G., Møller, J. H., Kørner, H., Gilje, B., Tjensvoll, K., Birkemeyer, E., Reino Heikkilä, A., Smaaland, R., & Nordgård, O. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1233-5 · Cited by 41
KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment
Boissière‐Michot, F., Lopez‐Crapez, E., Frugier, H., Berthe, M.-L., Ho-Pun-Cheung, A., Assénat, E., Maudelondé, T., Lamy, P., & Bibeau, F. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.210 · Cited by 37
Self-citation
Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer
Pinto, P., Rocha, P., Veiga, I., Guedes, J. G., Pinheiro, M., Peixoto, A., Pinto, C., Fragoso, M., Sanches, E., Araújo, A., et al. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.07.003 · Cited by 37

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Self-citation
Hepatocellular carcinoma
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics
Best, M. G., Sol, N., Kooi, I., Tannous, J., Westerman, B. A., Rustenburg, F., Schellen, P., Verschueren, H., Post, E., Koster, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.018 · Cited by 916
Origins, structures, and functions of circulating DNA in oncology
Thierry, A. R., El Messaoudi, S., Gahan, P. B., Anker, P., & Stroun, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9629-x · Cited by 818
Self-citation

See all 678

Authors: Thierry, A. R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., Del Rio, M., Lamy, P.-J., Bibeau, F., Nouaille, M., Loriot, V., Jarrousse, A.-S., Molina, F., Mathonnet, M., Pezet, D., & Ychou, M.
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2014-03-23
Volume: 20
Issue: 4
Pages: 430-435
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/nm.3511
OpenAlex: W2135924719
Cited by: 678
References: 42
FWCI: 21.58
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources